Abstract: NAD(P)H quinone oxidoreductase 1 (NQO1) catalyzes reactions having a cyto-protective effect against redox cycling and oxidative stress. A single base polymorphism (C/T) at nucleotide 609 of the NQO1 gene impairs the stability and function of its protein. Its role in the development of diabetic nephropathy (DN) has not been deciphered. Therefore, this study aimed to evaluate the association of NQO1*2 (rs1800566) polymorphism with plasma NQO1 levels and DN. This study screened 600 participants including healthy controls (HC), type 2 diabetes mellitus without complications (T2DM) and diabetic nephropathy (DN): 200 each for studying NQO1*2 gene polymorphism using the PCR-RFLP. Plasma NQO1 levels were measured by ELISA. Analysis of variance and logistic regression were used to evaluate the association of NQO1 polymorphism with plasma NQO1 levels and DN. The allelic frequencies of NQO1*1/NQO1*2 were 0.88/0.12 in HC, 0.765/0.235 in T2DM and 0.65/0.35 in DN. Carriers of the NQO1*2 allele had significantly lower plasma NQO1 levels (p < 0.05) and revealed higher risk towards the development of DN (OR = 1.717, p = 0.010). NQO1*2 SNP is a functional polymorphism having a significant effect on NQO1 levels. Our results indicate that NQO1*2 genotype may increase susceptibility to DN in north Indian subjects with T2DM.
Introduction
Diabetic nephropathy (DN) is a leading cause of chronic kidney disease that progresses to end-stage renal disease (ESRD) affecting 30-40% of patients with type 2 diabetes mellitus (T2DM) (Remuzzi et al., 2002) . Hyperglycemiainduced oxidative stress (OS) is now recognized as the major factor in the development of diabetic complications like DN (Kawahito et al., 2009) . It is widely documented and accepted that OS is increased in diabetic conditions and is probably involved in pancreatic β-cell dysfunction found in T2DM along with its related complications (Tiedge et al., 1997; Kajimoto and Kaneto, 2004; Tiwari et al., 2009 ). Thus, susceptibility to develop diabetic complications and related tissue damage may be greatly influenced by genetic determinants of OS and anti-oxidant mechanisms.
The Keap1/Nrf2/ARE pathway plays a pivotal role in regulating the expression of genes that are crucial mediators of cellular defense against OS such as the NQO1 gene that encodes NAD(P)H quinone oxidoreductase 1 (NQO1) (Ramprasath et al., 2012) . NQO1 originally called DTdiaphorase, is a cytosolic enzyme which catalyzes twoelectron reduction of quinone compounds and prevents the generation of reactive oxygen species (ROS), thus protecting cells from oxidative damage (Dinkova-Kostova and Talalay, 2010) . The NQO1 gene is located on chromosome 16q22.1 and Traver et al. (1997) have described a non-synonymous single nucleotide polymorphism (SNP) at nucleotide position 609 on exon 6 of the NQO1 cDNA (rs1800566) (Traver et al., 1997) . The variant is a C/T transition resulting in a change at codon 187 which codes for serine amino acid in the protein in place of proline thereby leading to three phenotypes, i.e. wild-type (NQO1*1/*1) with complete enzyme activity, heterozygous (NQO1*1/*2) with ~3-fold decreased activity and homozygous mutant (NQO1*2/*2) (null) with very low enzyme activity (Kuehl et al., 1995; Moran et al., 1999) . Decreased NQO1 enzyme activity is caused by enhanced polyubiquination and proteosomal degradation of the mutant protein (Siegel et al., 2001) . Association studies have shown that this polymorphism is involved in certain oxidative stress-related diseases, such as cancer, diabetes and Alzheimer's disease Wan et al., 2005; Martin et al., 2009; Ramprasath et al., 2012) . NQO1*2 (rs1800566) variant has been studied in different populations and a wide variation is observed in the allelic frequency of this polymorphism across ethnic groups (Hu et al., 2014) . Therefore, understanding the molecular mechanisms underlying the pathogenesis of diabetic nephropathy are critical for the prevention and treatment of this disease. Despite the important role of OS in diabetic complications, the association of NQO1*2 polymorphism with NQO1 levels and susceptibility to DN remains unclear to date.
Thus, the present study aimed to investigate the association between NQO1*2 polymorphism and plasma NQO1 levels in patients of T2DM with and without nephropathy in a north Indian population.
Results

Participant characteristics
The demographic and biochemical parameters of all the groups are shown in Table 1 . The mean age of HC and patients of T2DM with and without nephropathy was 44.4±7.2, 53.8±9.3 and 56.5±9.1 years, respectively. There were no significant differences among the T2DM patients with and without nephropathy and HC with respect to sex distribution and BMI. Although, T2DM and DN patients were older than those with HC. Duration of diabetes was longer in T2DM than in DN. SBP and DBP were found to be significantly higher in T2DM and DN patients as compared to HC (p < 0.05). Significantly higher fasting, postprandial plasma glucose and HbA1c were observed in DN as compared to T2DM showing a poor glycemic control (p < 0.05). Creatinine, urea, and uric acid levels were significantly higher and estimated glomerular filtration rate (eGFR) was lower in DN than in T2DM group (p < 0.05).
Distinctive distribution of the NQO1*2 polymorphism in a north Indian population
The NQO1*2 genotyping was performed in all the participants. The observed NQO1 genotype frequencies were in accordance with the Hardy-Weinberg equilibrium in diseased patients and HC. The genotype and allele distribution of the NQO1*2 in respective groups NQO1*1/*1, NQO1*2/*2 and NQO1*1/*2 are shown in Table 2 . For NQO1*2 gene polymorphism at position 609, the frequency of wild homozygous (NQO1*1/*1), heterozygous (NQO1*1/*2), mutant homozygous (NQO1*2/*2) genotypes in HC, T2DM and DN subjects were 77%, 58%, 42%; 22%, 37%, 46% and 1%, 5%, 12%, respectively. The allele Significantly different from T2DM at p < 0.05.
frequencies of NQO1*1/NQO1*2 were 0.88/0.12 in HC, 0.765/0.235 in T2DM and 0.65/0.35 in DN, thus the frequency of NQO1*1 allele was highest and NQO1*2 allele was the lowest in HC whereas NQO1*2 allele was highest and NQO1*1 allele was lowest in DN.
Association of NQO1*2 genotype with NQO1 levels
NQO1 levels were significantly increased in both the diseased groups, however, it was highest in T2DM patients (8 times) followed by DN (3.5 times) vs. HC group (Table 3) . The correlation between NQO1*2 polymorphism and NQO1 levels in plasma was studied, and the results are shown in Table 3 . In all the genotypes, NQO1 levels were highest in T2DM vs. DN as compared to HC which were the lowest. However, NQO1*1 allele was associated with higher NQO1 levels and NQO1*2 allele with lower levels of NQO1. SNP NQO1*2 is a functional polymorphism as it was seen to influence plasma NQO1 levels and NQO1*2 allele was Significantly different from homozygous NQO1*1/*1 in study groups at p < 0.05. b Significantly different from heterozygous NQO1*1/*2 in study groups at p < 0.05. 
Association of NQO1*2 genotypes with increased susceptibility to T2DM and DN
Based on the data, evaluation of association at genotypic level is shown in Table 4 . Among DN and T2DM patients, the odds ratio (OR) for the development of DN was 1.72-fold higher in T2DM patients carrying the NQO1*2/*2 genotype than in those carrying NQO1*1/*1 or NQO1*1/*2 genotypes (95% CI = 1.133-2.600). A significant association was observed for NQO1*2 polymorphism in patients of T2DM when compared to HC (OR = 6.638, 95% CI = 1.427-30.876, p = 0.016). NQO1*2 polymorphism was shown to be associated with an increased risk of DN in comparison to HC (OR = 22.00, 95% CI = 5.075-95.376, p = 0.000). Therefore, NQO1*2 allele may increase the risk for developing DN in T2DM patients as well as HC.
Discussion
NQO1 plays a prominent role in maintaining cellular homeostasis and is essential component of the antioxidant defense system. It catalyzes metabolic detoxification of quinones and protects cells against chemical induced oxidative stress (OS) and cancer (Lee et al., 2015) . Normally in human tissues, the expression of NQO1 is at minimal levels (Sankaranarayanan and Jaiswal, 2004) . This low level of expression is negatively controlled by the nuclear factor erythroid-2-related factor 3 (Nrf3) transcription factor, whereas the nuclear factor erythroid-2-related factor 2 (Nrf2) transcription factor, has a positive effect on NQO1 expression which is its downstream target gene (Sankaranarayanan and Jaiswal, 2004) . The above mentioned two transcription factors attach to the antioxidant response element (ARE) on the NQO1 promoter and control the expression process of the downstream gene.
Expression of NQO1 increases in response to oxidant and electrophilic radicals to counteract OS, and in fact, it is a kind of cytoprotective defense mechanism for cells (Sankaranarayanan and Jaiswal, 2004) . To date, there is no study reported for NQO1*2 SNP in patients of T2DM with and without nephropathy and its association with NQO1 levels and risk for DN. Hence, our study is probably the first one to depict the association of NQO1*2 polymorphism in the pathogenesis of DN in patients of T2DM with and without nephropathy which was further linked with NQO1 levels. In the present data, the frequency of NQO1*2/*2 allele is 35% in DN patients as compared to 23.5% in T2DM elucidating a significantly increased number of subjects carrying the NQO1*2/*2 allele genotype among DN patients in comparison to T2DM and HC. The frequency of NQO1*2 allele is consistent with the previous studies performed in various oxidative stress linked cancers, in Asian and European populations (Zhang et al., 2003; Chao et al., 2006; Malik et al., 2010) , but was in contrast with Chinese and Indian populations (Kolkata region) (Zhang et al., 2003; Parihar and Chauhan, 2010) .
On assaying by logistic regression to ascertain the genetic risk for the development of nephropathy in patients with T2DM, we have noted that patients with T2DM having NQO1*1/*2 and NQO1*2/*2 SNPs at 609 position of the NQO1 gene were found to have increased probability of developing nephropathy. However, the underlying probable mechanism for the correlation of NQO1*2 polymorphism with the increased risk for developing DN likely resides in the distinct enzyme activities encoded by the NQO1 alleles. Thus, low NQO1 activity encoded by the homozygous mutant (NQO1*2/*2) genotype may result in its decreased antioxidant and detoxification activity leading to a disturbed redox milieu, thereby increasing the disposition to OS mediated diseases viz. T2DM and DN. Preceding studies have also shown that NQO1*2 polymorphism in the NQO1 gene affects translation of its protein and has also been associated with an increased susceptibility to various malignancies, including renal, lung, esophageal, gastric and uterine cervix cancers which are considered to involve amplified OS in their progression (Schulz et al., 1997; Liu and Zhang, 2011; Malik et al., 2012; Lin et al., 2014; Ma et al., 2014) . There is no related study available in patients of diabetes or DN patients to support our findings. More importantly, we observed a significant difference in the levels of NQO1 with respect to genotypes within different study groups. This indicates that reduced NQO1 levels might play an important role in the progression of DN as it compromises the antioxidant arsenal to scuffle against the oxidative damage by elevated OS caused due to hyperglycemia. We have observed that NQO1 levels are increased in both the diseased groups as compared to HC. This increase could be due to enhanced expression of the NQO1 gene in response to heightened OS, however the rise in NQO1 protein levels in DN seems to be compromised despite exaggerated OS conditions viz: increased malondialdehyde (MDA), glutathione-S-transferase (GST) and decreased reduced glutathione (GSH) and ferric reducing ability of plasma (FRAP) suggesting that either the system is overburdened or there is interference with Nrf2/ARE system by uremic conditions (Bolati et al., 2013) . Compatible with these findings, it is highlighted from our experimental work that people carrying NQO1*2 SNP along with reduced enzyme activity may be more prone to DN. To summarize, our data suggests that the NQO1*2 gene polymorphism along with NQO1 levels may influence the susceptibility to DN in a north Indian population.
Conclusion
The present study provides additional information that determination of the NQO1*2 genotype might be a useful genetic marker in predicating individuals at high risk for the development of DN. Further studies are necessary to verify these associations among different ethnic populations which may give clinical benefit to diabetic patients with and without nephropathy.
Materials and methods
Ethics statement
This study complied with the Helsinki Declaration and was approved by the Institutional Ethics Committee for Human Research. Written informed consent was obtained from each participant after a brief and clear explanation about the potential use of their stored blood sample for scientific research and their privacy would be maintained.
Subjects
This case-control study recruited 400 patients with T2DM with and without nephropathy each, attending the Medicine OPD/Nephrology Outpatient Clinic at Guru Teg Bahadur Hospital, Delhi and 200 healthy controls who were volunteers and staff members of UCMS and GTB Hospital between November 2012 and March 2015. These participants were divided into three groups (n = 200 each) viz; group 1: healthy controls (HC), group 2: patients with T2DM for ≥ 10 years duration without complications (T2DM), group 3: patients with T2DM for ≥ 5 years with nephropathy (DN) stage 3 to stage 5. Diagnosis of T2DM was made according to revised American Diabetic Association (ADA) criteria (American Diabetic Association, 2015) . Proteinuria was detected by commercially available urinary dipsticks (Piramal Diagnostic, India, sensitivity of the dipstick 'Urine Test 11 MAU' is 10-15 mg/ dl). Participants with dipstick positive proteinuria were recruited in group 3. All group 3 patients had retinopathy, however, patients with macrovascular complications like stroke and coronary artery disease were excluded. Patients on inhibitors of renin-angiotension aldosterone system analogs were advised to discontinue these drugs for a week before inclusion in the study because they have been found to decrease the oxidative stress status (Pacurari et al., 2014) . To avoid potential confounding factors, patients with acute and chronic infections, fever, malignancy, congestive heart failure, cirrhosis of liver and other renal disorders were excluded. The protocol of the present study was approved by the Institutional Ethics Committee for Human Research and informed written consent was taken from all the participants. HC selected were all normotensive and normoglycemic.
Biochemical parameters
Demographic (age and sex) and anthropometric (weight, size, waist circumference and blood pressure) data were collected. Body mass index was calculated as weight in kilograms/height in meters squared. Systolic and diastolic blood pressure was measured in the sitting position after resting for at least 10 min using an automatic electronic sphygmomanometer. A fasting blood sample was withdrawn under aseptic conditions from the ante-cubital vein and collected into EDTA and fluoride vacutainers. For glycosylated hemoglobin, 200 μl whole blood was kept at 4-8°C, and was estimated within 1 week of collection by ion-exchange resin chromatography with commercially available kits (Fortress, UK). 100 μl of whole blood were stored at -20°C for DNA extraction and was processed within 2 days. The rest of the EDTA blood sample was centrifuged at 1008 g for 10 min and plasma was separated and stored in aliquots at -80°C till further use for the estimation of NQO1. Routine biochemical investigations such as fasting and post-prandial blood glucose, urea, creatinine and uric acid were carried out with an AU 400 Olympus autoanalyzer (Beckman Coulter, USA) and Star-21 semi-autoanalyzer (Rapid Diagnostic, India) using commercial kits. All the mentioned investigations were estimated once at the time of entry into the study.
Estimation of NAD(P)H quinone oxidoreductase 1(NQO1)
NQO1 was assayed by ELISA using commercially available kits (Cloud-Clone, USA; sensitivity < 0.116 ng/ml). The NQO1 concentration in the samples was measured by comparing the optical density of the samples to the standard curve and was represented in ng/ml.
DNA isolation and NQO1 genotyping by PCR and restriction fragment analysis
Genomic DNA was isolated from 100 μl of peripheral venous blood using commercially available DNA isolation kit (Zymo Research, USA). For the determination of the polymorphism of NQO1*2, genotyping was performed as the base change at nucleotide 609 of NQO1 cDNA draws a Hinf I restriction site, which was exploited by polymerase chain reaction (PCR) and subsequent restriction fragment length polymorphism (RFLP) analysis (Eickelmann et al., 1994) . The PCR was performed using the Eppendorf Mastercycler Gradient-5331 Thermocycler (Marshall Scientific, USA). Briefly, 100 ng of DNA was amplified in a 20 μl reaction mixture containing 10 pmol forward primer (5'-AGC CCA GAC CAA CTT CT-3') and 10 pmol reverse primer (5'-ATT TGA ATT CGG GCG TCT GCT G-3') and Maxima Hot start PCR master mix (2 × ) (Thermo Fisher Scientific Inc., USA). The protocol for amplification included an initial denaturation for 4 min at 95°C was followed by 35 cycles at 95°C for 30 s, 55°C for 30 s and 72°C for 1 min. Subsequently, PCR product was digested with 5U of Hinf I (Thermo Fisher Scientific Inc., USA) for 1 h at 37°C and enzyme was inactivated by incubating at 65°C for 20 min. The digested products were separated on a 3% agarose gel using ethidium bromide dye. The final PCR product of NQO1*2 was 172 bp. The NQO1*1/*1 allele exhibits a 172 bp PCR product resistant to enzyme digestion, although NQO1*2/*2 allele shows a 131 bp and a 41 bp band and these bands were visualized on the UVP DIGI DOC-IT (Ultra-Violet Product, UK) Gel Documentation system.
Statistical analysis
Statistical analysis were computed using SPSS version 17. The results were expressed as mean±SD. One-way analysis of variance (ANOVA) followed by post-hoc Tukey's test was used for comparing the demographic profile and biochemical parameters among the different subject groups. To compare the genotypic profile in all the study groups two-way ANOVA followed by post-hoc Tukey's test was used. Association of genotypes with levels of NQO1 was performed using analysis of variance. Logistic regressions for OR were assessed to test for associations at single SNP level for allele and genotype frequencies. Power of sample size for each SNP at 5% significance level and 80% power were calculated by genetic power calculator, and sample size was kept accordingly. This study followed Hardy-Weinberg equilibrium that used χ 2 test (in excel 2007). A p value < 0.05 was considered statistically significant (two-tailed).
